167 related articles for article (PubMed ID: 30901393)
21. Preventing herpes zoster through vaccination: New developments.
Le P; Sabella C; Rothberg MB
Cleve Clin J Med; 2017 May; 84(5):359-366. PubMed ID: 28530894
[TBL] [Abstract][Full Text] [Related]
22. Predictors of herpes zoster vaccination among Australian adults aged 65 and over.
Ricks T; Trent MJ; MacIntyre CR
Vaccine; 2022 Nov; 40(50):7182-7186. PubMed ID: 36336528
[TBL] [Abstract][Full Text] [Related]
23. Current and future effects of varicella and herpes zoster vaccination in Germany - Insights from a mathematical model in a country with universal varicella vaccination.
Horn J; Karch A; Damm O; Kretzschmar ME; Siedler A; Ultsch B; Weidemann F; Wichmann O; Hengel H; Greiner W; Mikolajczyk RT
Hum Vaccin Immunother; 2016 Jul; 12(7):1766-76. PubMed ID: 26835890
[TBL] [Abstract][Full Text] [Related]
24. Assessing the effectiveness of zoster vaccine live: A retrospective cohort study using primary care data in the United Kingdom.
Matthews I; Lu X; Dawson H; Bricout H; O'Hanlon H; Yu E; Nozad B
Vaccine; 2018 Nov; 36(46):7105-7111. PubMed ID: 30195489
[TBL] [Abstract][Full Text] [Related]
25. Effectiveness of Herpes Zoster Vaccine in Patients 60 Years and Older With End-stage Renal Disease.
Tseng HF; Luo Y; Shi J; Sy LS; Tartof SY; Sim JJ; Hechter RC; Jacobsen SJ
Clin Infect Dis; 2016 Feb; 62(4):462-7. PubMed ID: 26671505
[TBL] [Abstract][Full Text] [Related]
26. Vaccination against zoster remains effective in older adults who later undergo chemotherapy.
Tseng HF; Tartof S; Harpaz R; Luo Y; Sy LS; Hetcher RC; Jacobsen SJ
Clin Infect Dis; 2014 Oct; 59(7):913-9. PubMed ID: 25097079
[TBL] [Abstract][Full Text] [Related]
27. Herpes zoster vaccine effectiveness and manifestations of herpes zoster and associated pain by vaccination status.
Marin M; Yawn BP; Hales CM; Wollan PC; Bialek SR; Zhang J; Kurland MJ; Harpaz R
Hum Vaccin Immunother; 2015; 11(5):1157-64. PubMed ID: 25806911
[TBL] [Abstract][Full Text] [Related]
28. Longterm Effectiveness of Herpes Zoster Vaccine among Patients with Autoimmune and Inflammatory Diseases.
Yun H; Xie F; Baddley JW; Winthrop K; Saag KG; Curtis JR
J Rheumatol; 2017 Jul; 44(7):1083-1087. PubMed ID: 28298565
[TBL] [Abstract][Full Text] [Related]
29. Herpes Zoster Vaccine Coverage in Older Adults in the U.S., 2007-2013.
Zhang D; Johnson K; Newransky C; Acosta CJ
Am J Prev Med; 2017 Jan; 52(1):e17-e23. PubMed ID: 28340974
[TBL] [Abstract][Full Text] [Related]
30. Immunogenicity, reactogenicity and safety of 2 doses of an adjuvanted herpes zoster subunit vaccine administered 2, 6 or 12 months apart in older adults: Results of a phase III, randomized, open-label, multicenter study.
Lal H; Poder A; Campora L; Geeraerts B; Oostvogels L; Vanden Abeele C; Heineman TC
Vaccine; 2018 Jan; 36(1):148-154. PubMed ID: 29174683
[TBL] [Abstract][Full Text] [Related]
31. Effectiveness and Duration of Protection Provided by the Live-attenuated Herpes Zoster Vaccine in the Medicare Population Ages 65 Years and Older.
Izurieta HS; Wernecke M; Kelman J; Wong S; Forshee R; Pratt D; Lu Y; Sun Q; Jankosky C; Krause P; Worrall C; MaCurdy T; Harpaz R
Clin Infect Dis; 2017 Mar; 64(6):785-793. PubMed ID: 28362955
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of the incidence of herpes zoster after concomitant administration of zoster vaccine and polysaccharide pneumococcal vaccine.
Tseng HF; Smith N; Sy LS; Jacobsen SJ
Vaccine; 2011 May; 29(20):3628-32. PubMed ID: 21435407
[TBL] [Abstract][Full Text] [Related]
33. Herpes zoster vaccine and the incidence of recurrent herpes zoster in an immunocompetent elderly population.
Tseng HF; Chi M; Smith N; Marcy SM; Sy LS; Jacobsen SJ
J Infect Dis; 2012 Jul; 206(2):190-6. PubMed ID: 22669900
[TBL] [Abstract][Full Text] [Related]
34. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.
Hornberger J; Robertus K
Ann Intern Med; 2006 Sep; 145(5):317-25. PubMed ID: 16954357
[TBL] [Abstract][Full Text] [Related]
35. Zostavax : a subcutaneous vaccine for the prevention of herpes zoster.
Doan HQ; Ung B; Ramirez-Fort MK; Khan F; Tyring SK
Expert Opin Biol Ther; 2013 Oct; 13(10):1467-77. PubMed ID: 23984934
[TBL] [Abstract][Full Text] [Related]
36. Chickenpox exposure and herpes zoster disease incidence in older adults in the U.S.
Chaves SS; Santibanez TA; Gargiullo P; Guris D
Public Health Rep; 2007; 122(2):155-9. PubMed ID: 17357357
[TBL] [Abstract][Full Text] [Related]
37. Immunogenicity and Safety of the HZ/su Adjuvanted Herpes Zoster Subunit Vaccine in Adults Previously Vaccinated With a Live Attenuated Herpes Zoster Vaccine.
Grupping K; Campora L; Douha M; Heineman TC; Klein NP; Lal H; Peterson J; Vastiau I; Oostvogels L
J Infect Dis; 2017 Dec; 216(11):1343-1351. PubMed ID: 29029122
[TBL] [Abstract][Full Text] [Related]
38. Cost-Effectiveness of Herpes Zoster Vaccine for Persons Aged 50 Years.
Le P; Rothberg MB
Ann Intern Med; 2015 Oct; 163(7):489-97. PubMed ID: 26344036
[TBL] [Abstract][Full Text] [Related]
39. Risk of Herpes Zoster and Disseminated Varicella Zoster in Patients Taking Immunosuppressant Drugs at the Time of Zoster Vaccination.
Cheetham TC; Marcy SM; Tseng HF; Sy LS; Liu IL; Bixler F; Baxter R; Donahue JG; Naleway AL; Jacobsen SJ
Mayo Clin Proc; 2015 Jul; 90(7):865-73. PubMed ID: 26051268
[TBL] [Abstract][Full Text] [Related]
40. Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster.
Mills R; Tyring SK; Levin MJ; Parrino J; Li X; Coll KE; Stek JE; Schlienger K; Chan IS; Silber JL
Vaccine; 2010 Jun; 28(25):4204-9. PubMed ID: 20416263
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
